Skip to content

The Effect of Metacognition-based, Manualized Intervention on Fear of Cancer Recurrence

The Effect of Metacognition-based, Manualized Intervention on Fear of Cancer Recurrence: a Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04568226
Enrollment
177
Registered
2020-09-29
Start date
2021-07-21
Completion date
2024-02-03
Last updated
2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fear of Cancer Recurrence

Keywords

Fear of cancer recurrence, Metacognition, Cancer survivorship, Psychooncology, Breast cancer, Colorectal cancer, Gynecologic cancer

Brief summary

The primary aim of this study is to assess the effect of ConquerFear, a metacognition-based manualized intervention on fear of cancer recurrence, using the randomized controlled trial approach, among Chinese patients newly diagnosed with curable cancer. This study aims to (1) test the direct effect of ConquerFear intervention on fear of cancer recurrence and on maladaptive metacognition, and (2) to test the indirect effect of ConquerFear intervention on fear of cancer recurrence through its effect on maladaptive metacognition.

Detailed description

A randomized controlled trial will be conducted to test the effect of a metacognition-based manualized intervention on fear of cancer recurrence among Chinese breast, gynecologic and colorectal cancer patients with high levels of fear of cancer recurrence. The aims are to test: 1. the direct effect of ConquerFear intervention on fear of cancer recurrence, 2. the direct effect of ConquerFear intervention on maladaptive metacognition 3. the indirect effect of ConquerFear intervention on fear of cancer recurrence through its effect on maladaptive metacognition. Primary hypothesis: 1. Participants in the ConquerFear intervention will show a greater reduction in fear of cancer recurrence compared to participants in the control group 2. Participants in the ConquerFear intervention will show a greater reduction in maladaptive metacognition than the control participants 3. There will be an indirect effect of ConquerFear intervention on fear of cancer recurrence through its effect on maladaptive metacognition.

Interventions

ConquerFear is a manualized intervention, consists of six individual sessions over 10 weeks. The key goals of this intervention are the following: (1) teach strategies for controlling worry and excessive threat monitoring, (2) modify underlying unhelpful beliefs about worry, (3) develop appropriate monitoring and screening behaviours, (4) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (5) clarify values and encourage engagement in values-based goal setting (19). Each session will last 60-90 minutes and be delivered by a trained therapist. After each session, participants will be given home-based exercises to practice the skills learned in the sessions. With the uncertainty surrounding the COVID-19 pandemic, instead of face-to-face sessions only, a hybrid mode of intervention delivery will be used by offering participants the choice of face-to-face or online sessions.

OTHERActive control: Basic Cancer Care

Basic Cancer Care intervention for the control arm was developed to help cancer survivors with health maintenance in long-term through providing comprehensive lifestyle guidance. The intervention incorporates relaxation training, dietary and physical fitness consultations with the key goals to (1) teach relaxation techniques, (2) offer personalized diet and physical activity advice, and (3) enhance survivors' perceived control over illness, thereby leading to better adjustment to cancer. Similar to the ConquerFear intervention, Basic Cancer Care intervention consists of 6 individual sessions over 10 weeks. Each session will last 60-90 minutes and be delivered by a trained therapist, a registered dietitian, and an exercise physiologist, respectively. A hybrid mode of intervention delivery will be also used by offering participants the choice of face-to-face or online sessions.

Sponsors

Research Grants Council, Hong Kong
CollaboratorOTHER
The University of Hong Kong
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

The investigator, care provider, and outcomes assessor are masked in terms of not knowing to which condition the participants will be randomized until after the completion of the baseline assessment. The outcomes assessor will break the envelope for the next eligible participant indicating if that participant is to be allocated to ConquerFear or control arms. The participants are masked in terms of not knowing that one intervention (i.e. Conquer fear) is hypothesized to yield larger effects than the other (i.e. control).

Intervention model description

We will use a block randomization structure with randomly permuted block sizes of 2,4, and 6 to ensure a close balance of the numbers in each arm. Randomization (by a statistician) occurs prior to eligible patients attending the clinic to minimize opportunities for selection bias. We will also use a block randomization structure with randomly permuted block sizes of 4 and 8 to ensure an equal case allocation to each therapist. We will also use a block randomization structure with randomly permuted block sizes of 2,4, and 6 to ensure an equal case allocation to each dietitian.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Cantonese- or Mandarin-speaking Chinese patients recently diagnosed with non-metastatic breast cancer, gynecologic cancer, or colorectal cancer 2. had surgery as a primary treatment 3. have had completed hospital-based adjuvant treatments including radiotherapy and chemotherapy within the past 18 months 4. with the cut-off scored ≥ 13 on Severity, the subscale of Fear of cancer inventory 5. are able to read and write Chinese 6. are over the age of 18 years

Exclusion criteria

1. non-Chinese ethnicity 2. Patients diagnosed with metastatic cancer 3. with a current diagnosis of depression or psychosis 4. currently receiving psychological treatment 5. with language difficulties or intellectual disability.

Design outcomes

Primary

MeasureTime frameDescription
Fear of cancer recurrenceBaseline, immediate post-intervention, 3months post-intervention, and 6months post-interventionThe 42-items Fear of cancer recurrence inventory comprised of seven subscales will be used to assess the change of fear of cancer recurrence (FCR). Each item is rated on a 5-point Likert Scale with a total score ranging from 0 to 168. Higher scores indicate greater FCR. The subscale, Severity will be used as a screening tool for high level of FCR. A score of 13 or higher was optimal for screening.

Secondary

MeasureTime frameDescription
MetacognitionsBaseline, immediate post-intervention, 3months post-intervention, and 6monthsThe 30-items Metacognitions questionnaire (MCQ-30) will be used to assess the change of metacognitive beliefs.Each item is rated on a 4-point Likert scale with a total score ranging from 30 to 120. High scores indicate a more maladaptive metacognitive style.
EORTC QLQ-C30Baseline, immediate post-intervention, 3months post-intervention, and 6months post-interventionQuality of life (QoL) will be assessed by the EORTC QLQ-C30, in which incorporates five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and a number of single items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhoea) and perceived financial impact of the disease.
Self-efficacyBaseline, immediate post-intervention, 3months post-intervention, and 6months post-interventionSelf-efficacy for managing chronic disease will be assessed using the Self-Efficacy for Managing Chronic Disease 6-item Scale.
Coping behaviorBaseline, immediate post-intervention, 3months post-intervention, and 6months post-interventionCoping behavior will be assessed using the 28-item Chinese Brief COPE.
Experimental avoidanceBaseline, immediate post-intervention, 3months post-intervention, and 6months post-interventionExperimental avoidance will be assessed using the Acceptance and action questionnaire.
Cognitive Attentional SyndromeBaseline, immediate post-intervention, 3months post-intervention, and 6months post-interventionCognitive Attentional Syndrome (CAS) will be assessed using the Cognitive-attentional Syndrome questionnaire (CAS-1).
Therapeutic allianceImmediate post-interventionThe 12-item Working Alliance Inventory (WAI-SF)will be used to assess agreement on the therapy goal, patients' agreement with the therapist, and quality of the interpersonal bond. Both the participants and therapists will be asked to fill in the WAI-SF immediate post-intervention
Treatment satisfactionImmediate post-interventionTreatment satisfaction will be assessed using the evaluation form. Participants will be asked to indicate their overall satisfaction with the intervention they have received.
Intolerance of uncertaintyBaseline, immediate post-intervention, 3months post-intervention, and 6months post-interventionIntolerance of uncertainty (IU) will be assessed using the 12-item Intolerance of uncertainty-12.
Psychological distressBaseline, immediate post-intervention, 3months post-intervention, and 6months post-interventionPsychological distress will be assessed using the Hospital Anxiety and Depression Scale (HADS). HADS is a 14-item measure of anxiety and depression widely used to assess cancer-related distress.
Cancer-related distressBaseline, immediate post-intervention, 3months post-intervention, and 6months post-interventionThe 22-item Chinese Impact of Events Scale-revised (CIES-R) will be used to assess cancer-related distress, which comprised three subscales: avoidance, intrusive thoughts and hyperarousal symptoms measured using 5-point Likert scales. Higher mean scores on each subscale indicate greater avoidance/intrusiveness/arousal.
Treatment expectancyBaseline and immediate post-interventionTreatment expectancy will be assessed using the 6-item credibility/ expectancy questionnaire.

Other

MeasureTime frameDescription
Demographic dataBaselineDemographic data including age, gender, marital status, education level, occupation and monthly family income will be assessed by self-reported questionnaire
Clinical dataBaseline, immediate post-intervention, 3months post-intervention, and 6months post-interventionClinical data will be extracted from medical records.

Countries

Hong Kong

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026